



AN OVERVIEW ON GOSSYPIN AS PHARMACEUTICALLY IMPORTANT PHYTOCONSTITUENT

Gayatri Jejurkar¹, Machindra Chavan²

1. PhD Research Scholar, Amrutvahini College of Pharmacy, Sangamner, Pune, MS, India.
2. PhD Research Guide, Amrutvahini College of Pharmacy, Sangamner, Pune, MS, India.

gayatrijejurkar87@gmail.com

ABSTRACT

Oils, food supplements, nutraceuticals, and dyestuffs are just few of the many examples of chemicals that can be derived from nature. Many of the capsules currently on the market come from natural resources such plants, animals, microorganisms, minerals, and marine life. The unique sun shades of plants, such as orange, yellow, and crimson, are caused by flavonoids, and one of the most important secondary flavonoids is benzo-c-pirone derivates. The unique safe to eat plant life that is also determined by within the typical human diet contains around 4000 flavonoids, including flavanols, flavonols, isoflavones, flavanones, flavanonols, and flavones. Gossypin, a flavonol glucoside, is one of the most important chemicals found in plants of the 'Malvaceae' family. Our comprehensive review of gossypin's research thus far has led us to the conclusion that it possesses a wide variety of beneficial actions. It also provides defence against the toxicity caused by beta-amyloid. Researchers from various fields of technology may benefit from the information provided in the present overview, which could help them design better treatments for a variety of illnesses. Based on the information provided in this review, we may draw the conclusion that Gossypin can be utilised to effectively treat a wide range of illnesses.

Key-words: Flavone, Gossypin, Phytochemistry, Pharmacological profile

1.0 INTRODUCTION

Flavonoids, a family of natural chemicals that are extremely abundant in all higher plants. Flavonoids can be broken down into more than ten distinct chemical classes. As a result, their chemical diversity is quite high; over 5,000 variants arising in nature have been catalogued thus far. This variability may explain why flavonoids have so many different biological actions [1, 5]. A lower incidence of cardiovascular disease, neurological ailment tumour, and other chronic diseases has been epidemiologically linked to eating of flavonoid-rich foods, especially

vegetables and fruits [6-9]. Several flavonoid-based formulations have showed promise in clinical studies for the treatment of bone loss, vascular disease, and cancer [10–14]. Majority of flavonoids in nature are found in form of flavonoid glycosides. Glycosylation results in a extensive range of variability in both the number and types of carbohydrate units added. Glycosylation significantly modifies in vivo bioavailability and potential pharmacological activities by affecting chemical and physical characteristics [15]. Systemic administration of gossypin [16], myricitrin [17–18], linarin [19], and hesperidin [20] has also been demonstrated to have antinociceptive effects. Research into the underlying molecular mechanisms that cause these central effects has yielded conflicting hypotheses about the roles played by specific receptors, enzymes, and ion channels. Anxiolysis, sedation, and antinociception are all mediated by similar neural pathways, yet flavonoid glycosides' effect on anxiety has received surprisingly little attention. Although opiates are typically used for their analgesic effects in the clinic [21]. In addition, morphine has been demonstrated in preclinical research to be an opioid agonist that, when administered peripherally or centrally, can result in anxiolysis [22, 23]. Second, the anxiolytic effect of benzodiazepines is widely believed to be mediated through the endogenous opioid system. Opioid antagonists, according to a number of research [24], can counteract the calming effects of benzodiazepines and barbiturates. In addition, anxiogenic phenotypes were observed in various tests of behaviour in mice lacking the delta opioid receptor compared to wild-type mice [25]. Third, several benzodiazepines have been reported to produce mild antinociceptive activities [26]. It is noteworthy to note that the $\alpha 2$ subunit of GABAA receptors mediates this GABAergic pain manage in spinal cord; this is the same subtype of GABAA receptors that regulates the anxiolytic effect [27]. It has been observed that the analgesic effects of morphine can be enhanced by injecting the benzodiazepine alprazolam [28-30] or the sedative flavonoid glycoside hesperidin [31].




Fig. no. 01: Structure of Gossypin

2.0 PHARMACOLOGICAL ACTIVITIES

2.1. Antidiabetic activity

Streptozotocin-induced diabetic rats received 20 mg/kg Gossypin for 30 days. Gossypin's antidiabetic effects were shown by lesser blood glucose and HbA1c levels and elevated plasma insulin and haemoglobin. Plasma protein and blood urea levels normalised and liver and muscle glycogen stores increased. These findings suggest gossypin lowers diabetes [32-34]. Gossypin inhibited glucose uptake in rat jejunum basolateral membrane vesicles (BLMV) in the presence of flavonoids [35].

2.2. Antiinflammatory activity of gossypin

Work on gossypin, chrysin, methyl hespiridin, and procumbentin revealed that the latter two exhibit antinociceptive activity, but only gossypin shown anti-inflammatory properties. Both gossypin and procumbentin suppress COX-2 activity in vitro [36]. One more study found that gossypin and other flavonoids prevented carrageenan-induced paw edoema in mice when given orally[37-40]. Flavonoids were tested for their impact on arachidonic acid metabolism in sonicated sheep platelets. These findings suggested that blocking lipoxygenase might be crucial to the anti-inflammatory effect [41].

2.3. Anticancer activity of gossypin

Gossypin was discovered to decrease cell proliferation in human glioma U251 cells while being rather harmless to healthy human astrocytes in studies examining its anticancer effects. These findings show that gossypin inhibits U251 cell proliferation via Chk1 and Cdc25C [42]. Gossypin's anticarcinogenic and anticancer activity was measured in mutant *Saccharomyces cerviseae* topo I and topo II inhibition experiments. It greatly reduces tumour burden in animals with solid tumours by blocking the growth of new blood vessels within the tumour mass. It also inhibited papilloma development in a mouse model of cutaneous papilloma caused by DMBA/croton oil[43]. Gossypin, which was isolated from *H. vitifolius*, was tested for its cytotoxic effect in vitro and was found to inhibit vero cell lines by 68.75% at a dosage of 1,000 mg. Gossypin's importance in the inhibition of carcinogenesis was further clarified by a study showing that it suppressed NF-kappa B activation in tumour cells[44-46].

2.4. Analgesic activity of gossypin

In a mouse model of acetic acid-induced pain, gossypin dose-dependently reduced writhing, whereas naloxone inhibited it. Gossypin's analgesic activity involves opiate receptors, as its pA2 values are similar to those of morphine-naloxone [47-50].

2.5. Antiallergic activity of gossypin

Using a mast cell driven allergy paradigm, researchers found that gossypin suppressed antipruritics, systemic anaphylactic responses, and histamine production in rats, suggesting that

the compound had anti-allergic properties. Gossypin blocks the effects of mast cells in triggering allergic reactions[51-55].

2.6. Antiviral activity of gossypin

HSV-2 & HSV-1 plaque growth in Vero cells: an evaluation of 12 flavonoids, including gossypin. Hesperetin and naringenin were found to be mainly proficient against herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) compared to other 11 flavonoids, including gossypin, which were tested[56-63].

2.7. Antioxidant activity of gossypin

Gossypin's antioxidant capacity was evaluated using in vitro antioxidant techniques, and results confirmed, like BHT, possesses significant antioxidant activity. Gossypin and BHT decrease DPPH radical contents by 88.52 and 91.45%, respectively, supporting its antioxidant activity [64–70]. Gossypin and a few other extracts were studied for their antioxidant activity, and at the quantities employed in the study, gossypin fared pretty well.

2.8. Effect of gossypin on CNS

Gossypin's anticonvulsant potential was evaluated using maximal electroshock convulsive techniques & seizures generated with results demonstrating a considerable reduction in the length of convulsion. Strychnine and maximal electroshock both cause tonic extensor convulsions, but gossypin considerably reduces both[71-76]. Prominent plus maze test used to determine anxiolytic effects of gossypin, myricitrin, and naringin. Both gossypin and naringin were found to be effective at a dose of 1 mg/kg, however at a level of 30 mg/kg, gossypin exhibited sedative and anxiolytic properties. These findings suggest that gossypin may exert its effects via several distinct central nervous system pathways[77–80]. Results from an acetic acid-induced writhing assay in mice indicated that pretreatment with gossypin greatly decreased development of acute tolerance to morphine, indicating its potential as a substitute for morphine[81]. The neurotransmitter systems involved in gossypin's antinociceptive impact were studied, specifically the cholinergic and gamma-aminobutyric acid (GABA) ones [82].

2.9. Effect of gossypin on CVS

To further understand its cardiovascular potential, gossypin's effect on cholesterol metabolism in HepG2 cells was studied, Gossypin therapy reduced overall cholesterol. Gossypin activates ERK to promote LDLR expression without SREBP-2 [83].

2.10. Effect of gossypin on GIT

In a dose-dependent study on mice, it was observed that the chemicals epicatechin, hydroxyethyl rutosides, and gossypin all slowed down the movement of food through the mouse digestive tract [84-87]. P-glycoprotein is an organ-specific member of the vast family

of efflux transporters. Nitrendipine's transport rate was found to be lower in the ileum thanks to the interaction of gossypin and chrysin than in the jejunum and duodenum. Gossypin, methyl hesperidin, diosmin, quercetin, and chrysin are only a few examples of bioflavonoids that inhibit nitrendipine transport[88].

2.11. Effect of gossypin on microorganism

It was shown to have antimicrobial properties after being isolated from *H. vitifolius* [89]. It was found to have a moderate effect on *E. coli* and *S. aureus*, a minor effect on *Pseudomonas aeruginosa* and *Salmonella typhi*, and no effect on some of tested fungi.

2.12. Toxicity study of gossypin

Three weeks of research into the protective effects of gossypin against lead toxicity revealed that it increased glutathione levels, decreased superoxide dismutase activity, and decreased reactive oxygen species. Gossypin's protective action was demonstrated by the fact that it considerably reduced the occurrence of these changes in the treatment group [90]. Gossypin's protective effects against sulphur mustard in mice were studied over a range of doses, carriers (including water, PEG-300, and DMSO), and time points. As opposed to DMSO, gossypin administered in PEG-300 was found to provide greater protection against sulphur mustard poisoning than water did [91-92]. Different phenolic and flavonoid compounds were tested for their ability to mitigate CCl₄'s cytotoxicity in rat hepatocytes. The release of alanine amine transferase was considerably reduced by gossypin [93]. Flavonoids were studied for their potential preventive role against sulphur mustard-induced toxicity & had no effect on the amount of GSH but significantly reduced the level of MDA, providing more evidence for the beneficial effects of flavonoids [94]. When compared to the gold standard, tocopherol acetate, flavonoids including gossypin and quercetin were found to be more effective at preventing death caused by sulphur mustard. Research also demonstrated that gossypin provides substantial protection against glutathione peroxidase [94].

2.12. Effect of gossypin on other systems

Based on this discovery, we can extrapolate that a higher concentration of hydroxyl groups will result in a greater inhibitory impact of flavonoids on PRL-3[95]. Flavonoids with cyclin-dependent kinase 2 (CDK2) binding properties were identified by docking 347 flavonoid derivatives into CDK2 crystal structure. Binding affinity assay with NMR measurements [96] supported the results of the docking investigation showing that gossypin has a strong structural fit with CDK2. Eleven flavonoids and four phenolic acids had their transient spectra and reaction rate constants examined, and the results showed that certain groups in the basic skeleton were required for the corresponding activities. The four chemicals gossypin,

gossypetin, bharangin, and quercetin were found to have much higher activity than the conventional medicines [97-99]. Evaluation of β -lactamase inhibition, inhibition type, and structure-activity relationships in a variety of flavonoids and phenolic acids. Noncompetitive inhibitory effects were seen for the flavonoid compounds fisetin, flavone, quercetin, catechin, and gossypin. The OH location in a molecule's structure also appears to be important [100,102].

3.0 CONCLUSION

Basic medical care and the vast majority of medicines were sourced from natural resources roughly 20-30 years ago. Several types of plants Many medical disorders are treated with derivative products. Many pharmaceuticals in current use The medication is derived from nature. There is still a great deal Medicines that have been utilised for centuries by the inhabitants of Africa and Asia. A wide variety of manmade and organic chemicals harvested from a wide range of organic and inorganic sources. Many botanical materials and products have been included in WHO's lists for this very reason. Substance used in medicine. Evolution of new foods Discusses the positive effects of advances in food science and technology on human health. Provided by sterols, Carotenoids, polyphenols, and anthocyanins, all of which are sourced from plants. As the use of natural ingredients grows, the discipline of food science opens itself to a new demographic of health-conscious shoppers. attachment The variety and abundance of secondary metabolites is remarkable. general Secondary-product metabolism entails Various kinds of vegetation. Flavonoids generate many different classes of phytochemicals, There are eight main categories for plants: flavonoids and flavanones Anthocyanidins, chalcones, flavonolignans, isoflavones, and flavones Chemistry and structure Chromosomes are hydrocarbons with a heterocyclic Substitution ring complexes of flavonoids At least a C.8000 So far, it's identity has been confirmed. Common occurrences of natural flavonoids include: Glycosides, include glucose, ribose, and xylose. Leaves, flowers, and other plant surfaces (not the core) are the primary sources of flavonol glycosides. Fresh produce, etc. Flavonols can be found in abundance in beverages like tea and red wine. The staples of the diet are tea, onions, and apples. Natural flavonol extracts sourced from the USA, the Netherlands, and Denmark. Flavonoids are a component of the European diet, with daily consumption of up to roughly 1 g possible.

4.0 REFERENCES

- [1]. Harborne JB, Williams CA (2000) Advances in flavonoid research since 1992. *Phytochemistry* 55:481–504.

- [2]. Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. *Pharmacol Ther* 96:67–202.
- [3]. Messina M, Ho S, Alekel DL (2004) Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. *Curr Opin Clin Nutr Metab Care* 7:649–658.
- [4]. Grendys EC Jr, Blessing JA, Burger R et al (2005) A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a gynaecologic oncology group study. *Gynecol Oncol* 98:249–253.
- [5]. Katsenis K (2005) Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. *Curr Vasc Pharmacol* 3:1–9.
- [6]. Fernandez SP, Wasowski C, Loscalzo LM et al (2006) Central nervous system depressant action of flavonoid glycosides. *Eur J Pharmacol* 539:168–176.
- [7]. Viswanathan S, Sambantham PT, Reddy K et al (1984) Gossypin induced analgesia in mice. *Eur J Pharmacol* 98:289–291.
- [8]. Meotti FC, Luiz AP, Pizzolatti MG et al (2006) Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the L-arginine-nitric oxide and protein kinase C pathways. *J Pharmacol Exp Ther* 316:789–796.
- [9]. Marti´nez-Va´zquez M, Ramı´rez Apan TO, Lastra AL et al (1998) A comparative study of the analgesic and anti-inflammatory activities of pectolinarin isolated from *Cirsium subcoriaceum* and linarin isolated from *Buddleia cordata*. *Planta Med* 64:134–137.
- [10]. Loscalzo LM, Wasowski C, Paladini AC et al (2008) Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. *Eur J Pharmacol* 580:306–313.
- [11]. Kissin I, Brown PT, Bradley EL Jr (1990) Sedative and hypnotic midazolam-morphine interactions in rats. *Anesth Analg* 71:137–143
- [12]. Zarrindast MR, Rostami P, Zarei M et al (2005) Intra cerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats. *Basic Clin Pharmacol Toxicol* 97:276–281.
- [13]. Shin IC, Kim HC, Swanson J et al (2003) Anxiolytic effects of acute morphine can be modulate by nitric oxide systems. *Pharmacology* 68:183–189.
- [14]. Agmo A, Galvan A, Heredia A et al (1995) Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. *Psychopharmacology (Berl)* 120:186–194.

- [15]. Filliol D, Ghozland S, Chluba J et al (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet* 25:195–200.
- [16]. Knabl J, Witschi R, Hošl K et al (2008) Reversal of pathological pain through specific spinal GABAA receptor subtypes. *Nature* 451:330–334.
- [17]. Pick CG (1997) Antinociceptive interaction between alprazolam and opioids. *Brain Res Bull* 42:239–243.
- [18]. Fernandez SP, Mewett KN, Hanrahan JR et al (2008) Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice. *Neuropharmacology* 55:900–907.
- [19]. File SE (2001) Factors controlling measures of anxiety and responses to novelty in the mouse. *Behav Brain Res* 125:151–157
- [20]. Tripoli E, Guardia ML, Giammanco S, Majo DD, Giammanco M. Citrus flavonoids: molecular structure, biological activity and nutritional properties: a review. *Food Chem* 2007; **104**: 466-79.
- [21]. de Souza Dos Santos MC, Gonçalves CF, Vaisman M, Ferreira AC, de Carvalho DP. Impact of flavonoids on thyroid function. *Food Chem Toxicol* 2011; **49**: 2495-502.
- [22]. Karioti A, Bilia AR, Skaltsa H. *Quercus ilex* L.: a rich source of polyacylated flavonoid glucosides. *Food Chem* 2010; **123**: 131-42.
- [23]. Trichopoulou A, Vasilopoulou E, Hollman P, Chamalides CH, FoufaE, Kaloudis TR, et al. Nutritional composition and flavonoid content of edible wild greens and green pies: a potential rich source of antioxidant nutrients in the Mediterranean diet. *Food Chem* 2000; **70**: 319-23.
- [24]. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. *Nutrition* 2002; **18**: 75-81
- [25]. Williams RJ, Spencer JP. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. *Free Radic Biol Med* 2012; **52**: 35-45
- [26]. Cook NC, Samman S. Flavonoids-chemistry, metabolism, cardioprotective effects, and dietary sources. *J Nutr Biochem* 1996; **7**: 66-76
- [27]. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. *J Nutr Biochem* 2002; **13**: 572-84
- [28]. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. *Nutr Res* 2004; **24**: 851-74

- [29]. Thamizhiniyan V, Vijayaraghavan K, Subramanian SP. Gossypin, a flavonol glucoside protects pancreatic beta-cells from glucotoxicity in streptozotocin-induced experimental diabetes in rats. *Biomed Prev Nutr* 2012; **2**(4): 239-45
- [30]. Gautam P, Flora SJ. Oral supplementation of gossypin during lead exposure protects alteration in heme synthesis pathway and brain oxidative stress in rats. *Nutrition* 2010; **26**: 563-70
- [31]. Yang B, Halttunen T, Raimo O, Price K, Kallio H. Flavonol glycosides in wild and cultivated berries of three major subspecies of *Hippophaë rhamnoides* and changes during harvesting period. *Food Chem* 2009; **115**: 657-64
- [32]. Rusak G, Gutzeit HO, Mqller JL. Structurally related flavonoids with antioxidative properties differentially affect cell cycle progression and apoptosis of human acute leukemia cells. *Nutr Res* 2005; **25**: 141-53
- [33]. Fernández SP, Wasowski C, Loscalzo LM, Granger RE, Johnston GA, Paladini AC, et al. Central nervous system depressant action of flavonoid glycosides. *Eur J Pharmacol* 2006; **539**: 168-76
- [34]. Kim JD, Liu L, Guo W, Meydani M. Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion. *J Nutr Biochem* 2006; **17**: 165-76
- [35]. Castillo-Muñoz N, Gómez-Alonso S, García-Romero E, Hermosín- Gutiérrez I. Flavonol profiles of *Vitis vinifera* white grape cultivars. *J Food Comp Anal* 2010; **23**: 699-705
- [36]. Makrisa DP, Kallithraka S, Kefalas P. Flavonols in grapes, grape products and wines: burden, profile and influential parameters. *J Food Comp Anal* 2006; **19**: 396-404.
- [37]. Merzlyak MN, Solovchenko AE, Smagin AI, Gitelson AA. Apple flavonols during fruit adaptation to solar radiation: spectral features and technique for non-destructive assessment. *J Plant Physiol* 2005; **162**:151-60
- [38]. Bonetti EP, Pierri L, Cumin R et al (1982) Benzodiazepine antagonist RO 15–1788: neurological and behavioral effects. *Psychopharmacology (Berl)* 78:8–18
- [39]. Ashton CH (2003) Insomnia and anxiety. In: clinical pharmacy and therapeutics, 3rd edn. Churchill Livingstone, Sydney, pp 423–438
- [40]. Ipser JC, Carey P, Dhansay Y, et al. (2006) Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. *Cochrane Database Syst Rev* CD005473
- [41]. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and anxiety. *Nat Rev Drug Discov* 4:775–790

- [42]. Marder M, Paladini AC (2002) GABAA-receptor ligands of flavonoid structure. *Curr Top Med Chem* 2:853–867
- [43]. Zitron E, Scholz E, Owen RW et al (2005) QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. *Circulation* 111:835–838
- [44]. Kobayashi T, Ikeda K, Ichikawa T et al (1995) Molecular cloning of a mouse G-protein-activated K⁺ channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. *Biochem Biophys Res Commun* 208:1166–1173
- [45]. Guasti L, Cilia E, Crociani O et al (2005) Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: evidence for coassembly of different subunits. *J Comp Neurol* 491:157–174
- [46]. Chu CP-Y (2006) Three Pharmacological studies on nicotinic acetylcholine receptors: b-amyloid peptides, flavonoids and aconotoxins. Ph. D Thesis, University of Sydney, Sydney
- [47]. Picciotto MR, Brunzell DH, Caldarone BJ (2002) Effect of nicotine and nicotinic receptors on anxiety and depression. *Neuro- Report* 13:1097–1106
- [48]. Meotti FC, Posser T, Missau FC et al (2007) Involvement of p38MAPK on the antinociceptive action of myricitrin in mice. *Biochem Pharmacol* 74:924–931
- [49]. Walle T (2004) Absorption and metabolism of flavonoids. *Free Radic Biol Med* 36:829–837
- [50]. Singh U, Wadhvani AM, Johri BM. *Dictionary of Economic Plants of India*. New Delhi: Indian Council of Agricultural Research; 1983:100.
- [51]. Vijayan P, Raghu C, Ashok G, Dhanaraj SA, Suresh B. Antiviral activity of medicinal plants of Nilgiris. *Indian J Med Res*. 2004;120:24-29.
- [52]. Cai Z, Li X, Katsumura Y. Interaction of hydrated electron with dietary flavonoids and phenolic acids: rate constants and transient spectra studied by pulse radiolysis. *Free Radic Biol Med*. 1999; 27:822-829.
- [53]. Babu BH, Jayram HN, Nair MG, Ajaikumar KB, Padikkala J. Free radical scavenging, antitumor and anticarcinogenic activity of gossypin. *J Exp Clin Cancer Res*. 2003;22:581-589.
- [54]. Yoon I, Lee KH, Cho J. Gossypin protects primary cultured rat cortical cells from oxidative stress-and beta-amyloid-induced toxicity. *Arch Pharm Res*. 2004;27:454-459.

- [55]. Ramaswamy S, Viswanathan S. Influence of gossypin on the development of acute tolerance to morphine induced antinociception. *Indian J Exp Biol.* 1997;35:413-414.
- [56]. Viswanathan S, Thirugnanasambantham P, Ramaswamy S, Bapna JS. A study on the role of cholinergic and gamma amino butyric acid systems in the anti-nociceptive effect of gossypin. *Clin Exp Pharmacol Physiol.* 1993;20:193-196.
- [57]. Anon MT, Ubeda A, Alcaraz MJ. Protective effects of phenolic compounds on CC14-induced toxicity in isolated rat hepatocytes. *Z Naturforsch [C].* 1992;47:275-279.
- [58]. Vijayaraghavan R, Sugendran K, Pant SC, Husain K, Malhotra RC. Dermal intoxication of mice with bis(2-chloroethyl)sulphide and the protective effect of flavonoids. *Toxicology.* 1991;69:35-42.
- [59]. Ferrandiz ML, Alcaraz MJ. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. *Agents Actions.* 1991;32:283-288.
- [60]. Aggarwal BB. Nuclear factor-kappaB: the enemy within. *Cancer Cell.* 2004;6:203-208.
- [61]. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-B through phosphorylation and degradation of I κ B: correlation with induction of cyclooxygenase-2. *Carcinogenesis.* 2002;23:1511-1518.
- [62]. Wang J, Wilcken DE, Wang XL. Cigarette smoke activates caspase-3 to induce apoptosis of human umbilical venous endothelial cells. *Mol Genet Metab.* 2001;72:82-88.
- [63]. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redox-sensitive transcription factor. *Methods Enzymol.* 2000;319:585-602.
- [64]. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I κ B and serine phosphorylation of p65: evidence for the involvement of I κ B kinase and Syk protein-tyrosine kinase. *J Biol Chem.* 2003;278:24233-24241.
- [65]. Manna SK, Mukhopadhyay A, Aggarwal BB. IFN alpha suppresses activation of nuclear transcription factors NF- κ B and activator protein 1 and potentiates TNF-induced apoptosis. *J Immunol.* 2000;165:4927-4934.
- [66]. Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation of NF- κ B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF- κ B-inducing kinase. Identification of a novel TRAF6 interaction motif. *J Biol Chem.* 1999;274: 7724-7731.
- [67]. Takada Y, Aggarwal BB. Flavopiridol inhibits NF- κ B activation induced by various carcinogens and inflammatory agents through inhibition of I κ B kinase and p65

- phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. *J Biol Chem.* 2004;279:4750-4759.
- [68]. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IB kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. *Cancer Res.* 2003;63:4375-4383.
- [69]. Ichikawa H, Takada Y, Murakami A, Aggarwal BB Identification of a novel blocker of IB kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-B-regulated gene products. *J Immunol.* 2005;174: 7383-7392.
- [70]. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF- B activation in osteoclast precursors and suppresses osteoclastogenesis. *J Immunol.* 2004;172:5940-5947.
- [71]. Zeng L, Yang S, Wu C, Ye L, Lu Y. Effective transduction of primary mouse blood- and bone marrow-derived monocytes/macrophages by HIV- based defective lentiviral vectors. *J Virol Methods.* 2006;134:66-73.
- [72]. Stafford LJ, Xia C, Ma W, Cai Y, Liu M. Identification and characterization of mouse metastasis- suppressor KiSS1 and its G-protein-coupled receptor. *Cancer Res.* 2002;62:5399-5404.
- [73]. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. *Leukemia.* 2002;16:1053-1068.
- [74]. Pahl HL. Activators and target genes of Rel NF-B transcription factors. *Oncogene.* 1999;18:6853-6866.
- [75]. Shishodia S, Aggarwal BB. Nuclear factor-B: a friend or a foe in cancer? *Biochem Pharmacol.* 2004;68:1071-1080.
- [76]. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the IB kinase alpha and beta subunits in liberating nuclear factor B (NF-B) from I B and in phosphorylating the p65 subunit of NF-B. *J Biol Chem.* 2002;277:3863-3869.
- [77]. Campbell KJ, Chapman NR, Perkins ND. UV stimulation induces nuclear factor B (NF-B) DNA-binding activity but not transcriptional activation. *Biochem Soc Trans.* 2001;29:688-691.
- [78]. Aggarwal BB. Signalling pathways of the TNF super family: a double-edged sword. *Nat Rev Immunol.* 2003;3:745-756.

- [79]. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with IB kinases to stimulate NF-B activation. *J Biol Chem.* 1999;274: 10641-10648.
- [80]. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAK1 is critical for IB kinase-mediated activation of the NF-B pathway. *J Mol Biol.* 2003;326:105-115.
- [81]. Zhu L, Fukuda S, Cordis G, Das DK, Maulik N. Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. *FEBS Lett.* 2001;508:369-374.
- [82]. Tamatani M, Che YH, Matsuzaki H, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFB activation in primary hippocampal neurons. *J Biol Chem.* 1999;274:8531-8538.
- [83]. Xiao CW, Ash K, Tsang BK. Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor alpha-induced apoptosis. *Endocrinology.* 2001;142:557-563.
- [84]. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor B and its significance in prostate cancer. *Oncogene.* 2001;20:7342- 7351.
- [85]. You M, Ku PT, Hrdlickova R, Bose HR Jr. chIAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. *Mol Cell Biol.* 1997;17:7328-7341.
- [86]. Schwenzler R, Siemienski K, Liptay S, et al. The human tumor necrosis factor (TNF) receptor- associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-B and c-Jun N-terminal kinase. *J Biol Chem.* 1999;274:19368-19374.
- [87]. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-B controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol.* 1999;19:5785-5799.
- [88]. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. *J Biol Chem.* 1995;270: 31315-31320.
- [89]. Duyao MP, Kessler DJ, Spicer DB, et al. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF B. *J Biol Chem.* 1992;267:16288-16291.

- [90]. Esteve PO, Chicoine E, Robledo O, et al. Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-B. *J Biol Chem.* 2002;277:35150-35155.
- [91]. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-B activation in endothelial cells. *J Biol Chem.* 2001;276:7614-7620.
- [92]. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-B activation to suppress p53-independent apoptosis induced by oncogenic Ras. *Science.* 1997;278:1812-1815.
- [93]. Giri DK, Aggarwal BB. Constitutive activation of NF-B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. *J Biol Chem.* 1998;273: 14008-14014.
- [94]. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science.* 1998; 281:1680-1683.
- [95]. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature.* 1999;397:315-323.
- [96]. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. *Clin Cancer Res.* 1999;5:119-127.
- [97]. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-B activation in human prostate cancer cells. *Prostate.* 2002;52:183-200.
- [98]. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-B activation in breast cancer cells. *Oncogene.* 2002;21:2066-2078.
- [99]. Tai DI, Tsai SL, Chang YH, et al. Constitutive activation of nuclear factor B in hepatocellular carcinoma. *Cancer.* 2000;89:2274-2281.
- [100]. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signalling in human multiple myeloma cells: therapeutic implications. *Oncogene.* 2002;21:5673-568
- [101]. Hurlin PJ, Dezfouli S. Functions of myc:max in the control of cell proliferation and tumorigenesis. *Int Rev Cytol.* 2004;238:183-226.

- [102]. Erickson LA, Jin L, Goellner JR, et al. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. *Mod Pathol.* 2000;13:186-192.